Lisata Therapeutics Appoints New Director
Ticker: LSTA · Form: 8-K · Filed: Apr 17, 2024 · CIK: 320017
Sentiment: neutral
Topics: board-appointment, management-change
TL;DR
Lisata Therapeutics adds Dr. Philip P. Vanek to its board.
AI Summary
Lisata Therapeutics, Inc. announced on April 15, 2024, a change in its Board of Directors. Specifically, Dr. Philip P. Vanek has been appointed as a new director, effective immediately. This appointment is part of the company's ongoing efforts to strengthen its leadership and strategic direction.
Why It Matters
The addition of a new director can signal strategic shifts or a focus on specific areas of expertise, potentially impacting the company's future direction and investor confidence.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low immediate risk.
Key Players & Entities
- Lisata Therapeutics, Inc. (company) — Registrant
- Dr. Philip P. Vanek (person) — Newly appointed director
- 001-33650 (company) — SEC File Number
- 22-2343568 (company) — I.R.S. Employer Identification No.
FAQ
Who is Dr. Philip P. Vanek and what is his background?
The filing does not provide specific details about Dr. Vanek's background or qualifications, only that he has been appointed as a director.
When was Dr. Philip P. Vanek's appointment effective?
Dr. Philip P. Vanek's appointment was effective as of April 15, 2024.
What is Lisata Therapeutics, Inc.'s principal executive office address?
Lisata Therapeutics, Inc.'s principal executive office is located at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
What is the SIC code for Lisata Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Lisata Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Has Lisata Therapeutics, Inc. had previous names?
Yes, Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. (name change effective 20170808), and prior to that, Caladrius Biosciences, Inc. (name change effective 20150608), and NeoStem, Inc. (name change effective 20060906).
Filing Stats: 779 words · 3 min read · ~3 pages · Grade level 10.8 · Accepted 2024-04-17 16:04:04
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LSTA The Nasdaq Capital Marke
- $350,000 — ensation for Mr. Nisco, consisting of a $350,000 annual base salary and a bonus short-te
Filing Documents
- clbs-20240415.htm (8-K) — 24KB
- 0000320017-24-000013.txt ( ) — 148KB
- clbs-20240415.xsd (EX-101.SCH) — 2KB
- clbs-20240415_lab.xml (EX-101.LAB) — 22KB
- clbs-20240415_pre.xml (EX-101.PRE) — 13KB
- clbs-20240415_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LISATA THERAPEUTICS, INC. By: /s/ David J. Mazzo Name: David J. Mazzo, PhD Title: President and Chief Executive Officer Dated: April 17, 2024